Alternative Treatment for Alzheimer’s Disease: Porphyromonas gingivalis Inhibitors

Porphyromonas gingivalis (P. gingivalis), has been identified as a primary pathogen in causing chronic periodontitis, or gum inflammation. P. gingivalis was also isolated in brain samples of patients suffering from Alzheimer’s disease. A virulence factor of P. gingivalis called gingipains, releases proteases responsible for neurodegeneration and has been identified in the brain of patients suffering from Alzheimer’s. Studies show that mice infected with P. gingivalis demonstrate an increase in amyloid plaque deposition in brain samples. Further investigation identified gingipains as a neurotoxic agent, both in vivo and in vitro, which impacts the structure of tau protein, responsible for the normal functioning of neurons. Small-molecule inhibitors targeting gingipains are utilized to prevent the neurotoxic effects of gingipains and facilitate neuronal regeneration. Inhibition of this virulence factor reduced the overall bacterial load, blocked amyloid-beta production, prevented neuroinflammation, and allowed for neuronal recovery. These findings provide a new outlook for the onset of Alzheimer’s disease and elucidate a much-needed potential treatment for the condition.